Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28327229 | 0.80 | NISCH (0.44) | NISCHNPC1RAB9AMAPTSCN5A | |
| SCHEMBL9480003 | 0.79 | RIPK1 (0.30) | — | |
| SCHEMBL9479947 | 0.73 | KIF11 (0.32) | — | |
| SCHEMBL10769227 | 0.71 | — | — | |
| SCHEMBL294190 | 0.71 | — | — | |
| SCHEMBL2564426 | 0.71 | DRD1 (0.36) | NPC1RAB9AMAPTSCN5ALMNA | |
| SCHEMBL19833847 | 0.70 | ABL1 (0.45) | NISCHNPC1RAB9AGPR3MAPT | |
| SCHEMBL3048497 | 0.68 | APP (0.40) | MAPT | |
| SCHEMBL9956819 | 0.67 | GPR3 (0.36) | NISCHGPR3MAPTEPHX2TP53 | |
| SCHEMBL319976 | 0.67 | NOS3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4146652-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | Merck Patent GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| EP-2375898-B1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-2177519-A1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | Nippon Soda Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | NISCH 2344/4885NPC1 1133/4885RAB9A 3142/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | NISCH 4392/4885NPC1 2281/4885RAB9A 1789/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | NISCH 2373/4885NPC1 2442/4885RAB9A 1605/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | NISCH 2373/4885NPC1 2442/4885RAB9A 1605/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | NISCH 3789/4885NPC1 2291/4885RAB9A 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.